Cell line isolation and design

Munro, Trent P., Pilbrough, Warren, Hughes, Benjamin S. and Gray, Peter P. (2011). Cell line isolation and design. In Murray Moo-Young, Michael Butler, Colin Webb, Antonio Moreira,, Bernard Grodzinski, Z. F. Cui and Spiros Agathos (Ed.), Scientific Fundamentals of Biotechnology 2nd ed. (pp. 169-178) Amsterdam, Netherlands: Elsevier. doi:10.1016/B978-0-08-088504-9.00024-6


Author Munro, Trent P.
Pilbrough, Warren
Hughes, Benjamin S.
Gray, Peter P.
Title of chapter Cell line isolation and design
Title of book Scientific Fundamentals of Biotechnology
Place of Publication Amsterdam, Netherlands
Publisher Elsevier
Publication Year 2011
Sub-type Chapter in textbook
DOI 10.1016/B978-0-08-088504-9.00024-6
Series Comprehensive Biotechnology
Edition 2nd
ISBN 9780444533524
0444533524
9780444538505
044453850X
9780080885049
0080885047
Editor Murray Moo-Young
Michael Butler
Colin Webb
Antonio Moreira,
Bernard Grodzinski
Z. F. Cui
Spiros Agathos
Volume number 1
Chapter number 13
Start page 169
End page 178
Total pages 10
Total chapters 51
Collection year 2012
Language eng
Formatted Abstract/Summary
Biotechnology and genetic engineering have facilitated a new generation of biology-based therapeutic agents known broadly as biopharmaceuticals. Many of these agents address otherwise untreatable diseases, and now represent a worldwide market of over US$100 billion per year. Most biopharmaceuticals are made in mammalian cell culture, because mammalian cells are capable of efficiently producing highly complex, biologically active molecules, such as monoclonal antibodies. Structurally complex live-attenuated and inactivated viral vaccines are also made using mammalian cell culture. Production cell lines for biopharmaceuticals are created by stable genomic integration of expression constructs encoding the genes of interest. This creates a pool of transfected cells that typically display large variations in expression level and other characteristics. For clinical and final manufacturing, single cell clones with the required productivity and product quality attributes are selected and isolated. This process is laborious, time-consuming, and typically represents a key rate-limiting step in early biologic drug development. To address these issues, efforts in the field have focused on developing automated, intelligent methods for cell selection and screening and on cell engineering for higher expression levels, improved manufacturing robustness, and better stability of production cell lines. In this article, we explore recent advances in clonal isolation and evaluation as well as developments in the field of designer cell lines for bioproduction.
Q-Index Code BX
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Published under "The Biological Basis".

 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Thu, 22 Sep 2011, 16:25:01 EST by Dr Trent Munro on behalf of Aust Institute for Bioengineering & Nanotechnology